These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 11923800

  • 1. Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study).
    Spertus JA, Tooley J, Jones P, Poston C, Mahoney E, Deedwania P, Hurley S, Pitt B, Weintraub WS.
    Am Heart J; 2002 Apr; 143(4):636-42. PubMed ID: 11923800
    [Abstract] [Full Text] [Related]

  • 2. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z, Mahoney EM, Kolm P, Spertus J, Caro J, Willke R, Weintraub WS.
    Am J Cardiovasc Drugs; 2010 Apr; 10(1):55-63. PubMed ID: 20104935
    [Abstract] [Full Text] [Related]

  • 3. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C, Burch J, Suekarran S, Walker S, Bakhai A, Witte K, Harden M, Wright K, Woolacott N, Lorgelly P, Fenwick L, Palmer S.
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
    de Pouvourville G, Solesse A, Beillat M.
    Arch Cardiovasc Dis; 2008 Sep; 101(9):515-21. PubMed ID: 19041835
    [Abstract] [Full Text] [Related]

  • 5. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy.
    Rossignol P, Ménard J, Fay R, Gustafsson F, Pitt B, Zannad F.
    J Am Coll Cardiol; 2011 Nov 01; 58(19):1958-66. PubMed ID: 22032706
    [Abstract] [Full Text] [Related]

  • 6. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
    Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J.
    Cardiovasc Drugs Ther; 2001 Jan 01; 15(1):79-87. PubMed ID: 11504167
    [No Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
    Weintraub WS, Zhang Z, Mahoney EM, Kolm P, Spertus JA, Caro J, Ishak J, Goldberg R, Tooley J, Willke R, Pitt B.
    Circulation; 2005 Mar 08; 111(9):1106-13. PubMed ID: 15723981
    [Abstract] [Full Text] [Related]

  • 8. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ, Howard PA.
    Ann Pharmacother; 2005 Jan 08; 39(1):68-76. PubMed ID: 15590870
    [Abstract] [Full Text] [Related]

  • 9. Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
    Carillo S, Zhang Y, Fay R, Angioi M, Vincent J, Sutradhor SC, Ahmed A, Pitt B, Zannad F.
    Arch Cardiovasc Dis; 2014 Mar 08; 107(3):149-57. PubMed ID: 24630753
    [Abstract] [Full Text] [Related]

  • 10. [Aldosterone receptor blockade after acute myocardial infarction with heart failure].
    Bauersachs J, Ertl G.
    Med Klin (Munich); 2006 Jun 15; 101(6):458-66. PubMed ID: 16767569
    [Abstract] [Full Text] [Related]

  • 11. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH, Abuissa H, Pitt B.
    Diabetes Obes Metab; 2008 Jun 15; 10(6):492-7. PubMed ID: 17490427
    [Abstract] [Full Text] [Related]

  • 12. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
    Gheorghiade M, Khan S, Blair JE, Harinstein ME, Krum H, Mukherjee R, Pitt B, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival (EPHESUS) Investigators.
    Am Heart J; 2009 Sep 15; 158(3):437-43. PubMed ID: 19699868
    [Abstract] [Full Text] [Related]

  • 13. Selective aldosterone blockade with eplerenone in patients with congestive heart failure.
    Salam AM.
    Expert Opin Investig Drugs; 2003 Aug 15; 12(8):1423-7. PubMed ID: 12882627
    [Abstract] [Full Text] [Related]

  • 14. Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS).
    Chan PS, Soto G, Jones PG, Nallamothu BK, Zhang Z, Weintraub WS, Spertus JA.
    Circulation; 2009 Jan 27; 119(3):398-407. PubMed ID: 19139382
    [Abstract] [Full Text] [Related]

  • 15. Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns.
    Ferreira JP, Duarte K, McMurray JJV, Pitt B, van Veldhuisen DJ, Vincent J, Ahmad T, Tromp J, Rossignol P, Zannad F.
    Circ Heart Fail; 2018 Jul 27; 11(7):e004926. PubMed ID: 29997240
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective.
    Szucs TD, Holm MV, Schwenkglenks M, Zhang Z, Weintraub WS, Burnier M, Erne P.
    Cardiovasc Drugs Ther; 2006 Jun 27; 20(3):193-204. PubMed ID: 16775667
    [Abstract] [Full Text] [Related]

  • 17. Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure.
    Croom KF, Plosker GL.
    Pharmacoeconomics; 2005 Jun 27; 23(10):1057-72. PubMed ID: 16235978
    [Abstract] [Full Text] [Related]

  • 18. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
    Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, EPHESUS Investigators.
    Circulation; 2008 Oct 14; 118(16):1643-50. PubMed ID: 18824643
    [Abstract] [Full Text] [Related]

  • 19. Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist.
    Verma A, Solomon SD.
    Curr Heart Fail Rep; 2007 Dec 14; 4(4):183-9. PubMed ID: 18221614
    [Abstract] [Full Text] [Related]

  • 20. New treasures from old? EPHESUS. Eplerenome Post-AHI Heart Failure Efficacy and Survival Study.
    Pfeffer MA.
    Cardiovasc Drugs Ther; 2001 Jan 14; 15(1):11-3. PubMed ID: 11504157
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.